STOCK TITAN
  1. Home
  2. News
  3. IRWD

Ironwood Pharmaceuticals Inc - IRWD STOCK NEWS

Welcome to our dedicated news page for Ironwood Pharmaceuticals (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ironwood Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ironwood Pharmaceuticals's position in the market.

News
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. announced positive results from the Phase II STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD). The trial showed that apraglutide was well-tolerated with an acceptable safety profile, and patients maintained lower GI tract responses through Day 91.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
clinical trial
-
News
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announces positive Phase III STARS trial results for apraglutide in reducing parenteral support dependency in adult patients with short bowel syndrome with intestinal failure. Apraglutide met primary endpoint of reducing PS volume at week 24, demonstrated improvement in patients achieving at least one day off PS, and plans to submit NDA for regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.63%
Tags
clinical trial
-
News
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. to present apraglutide data at ASPEN 2024 on treating adult patients with short bowel syndrome with intestinal failure. Apraglutide shows promise in reducing parenteral support needs and improving fluid and energy absorption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
conferences
News
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
Rhea-AI Summary
Ironwood Pharmaceuticals reports strong financial performance in 2023 with LINZESS® achieving $1.1 billion in U.S. net sales, a 7% increase year-over-year. The company also generated $443 million in revenue, mainly from LINZESS collaboration revenue. Ironwood continues to expect topline results from the STARS Phase III study of apraglutide in patients with short bowel syndrome in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
earnings
-
News
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will host its Q4 and full year 2023 investor update conference call and webcast on February 15, 2024. The call will be available for replay via telephone and archived on Ironwood's website for 1 year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
-
News
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announces new data from a Phase III study evaluating linaclotide in children and adolescents aged 6-17 years with functional constipation. The data, published in The Lancet Gastroenterology & Hepatology, highlights additional efficacy endpoints and formed the basis of the FDA approval of linaclotide for this population in June 2023. Functional constipation affects an estimated 6 million children in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
clinical trial
News
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 and anticipates 2024 adjusted EBITDA of greater than $150 million. The company announced this financial guidance ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference. CEO Tom McCourt expressed confidence in the company's strategic progress and position in the GI healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
-
News
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Live webcast accessible through company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
News
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) has successfully completed the squeeze-out merger with VectivBio Holding AG, resulting in the cancellation and conversion of all remaining outstanding ordinary shares of VectivBio into the right to receive $17.00 per share in cash. The merger was approved by VectivBio shareholders at an extraordinary general meeting. Ironwood also completed a tender offer to purchase approximately 97.5 percent of outstanding shares, followed by the voluntary delisting of VectivBio shares from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
acquisition
News
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The live webcast can be accessed through the Investors section of the company’s website. A replay will be available for 14 days following the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
Stock IRWD logo
Ironwood Pharmaceuticals Inc

Nasdaq:IRWD

IRWD Rankings

#2245 Ranked by Market Cap
#3314 Ranked by Stock Gains
N/A Ranked by Dividends

IRWD Stock Data

1.23B
137.03M
2.08%
108.94%
14.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IRWD

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b